Trastuzumab emtansine | 曲妥珠單抗-美坦新偶聯物

MCE 國際站：Trastuzumab emtansine

中文名：曲妥珠單抗-美坦新偶聯物

CAS：1018448-65-1

品牌：MedChemExpress (MCE)

存儲條件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：曲妥珠單抗 emtansine (Ado-Trastuzumab emtansine) 是一種抗體藥物偶聯物 (ADC)，它結合了曲妥珠單抗的 HER2 靶向抗腫瘤特性和微管抑制劑 DM1（美登素的衍生物）的細胞毒活性. Trastuzumab emtansine可用于晚期乳腺癌的研究^[1][2]。

^{體外：Trastuzumab emtansine (2 μg/mL; 3 d) 顯著抑制上皮性卵巢癌 (EOC) 細胞的增殖[2]。}

體內：Trastuzumab emtansine（15 mg/kg；每周靜脈注射 3 至 5 次，持續 3 周）在小鼠體內表現出顯著的抗腫瘤作用^[2]。

銷售產品：Masitinib  | Potassium 1H-indol-3-yl sulfate  | Ouabain (Octahydrate)  | L-778123 (hydrochloride)  | Romosozumab  | CHAPS  | 1,2-Distearoyl-sn-glycero-3-phosphorylcholine  | Denosumab  | Cobimetinib  | N,N,N′,N′-Tetracyclohexyl-3-oxapentanediamide

研究領域：Antibody-drug Conjugate/ADC Related  |  JAK/STAT Signaling  |  Protein Tyrosine Kinase/RTK

作用靶點：Antibody-Drug Conjugates (ADCs)  |  EGFR

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

參考文獻：

[1]. Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91.

[2]. Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017 Oct;147(1):145-152.